Mirum Pharmaceuticals Inc (MIRM) financials
Mirum Pharmaceuticals revenue and earnings by year
Mirum Pharmaceuticals's revenue was $521 million in the fiscal year to December 31, 2025, up 54.7% from the year before. Net income was -$23.4 million, -4.5% of revenue. Since the fiscal year to December 31, 2021, revenue has grown 128.5% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 5 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 521 | 337 | 186 | 77 | 19 |
| Revenue growth | 54.7% | 80.8% | 141.8% | 302.7% | — |
| Gross profit | 421 | 255 | 139 | 65 | 17 |
| Gross margin | 80.8% | 75.8% | 74.8% | 83.9% | 90.1% |
| Operating income | -22 | -88 | -109 | -131 | -173 |
| Operating margin | -4.2% | -26.0% | -58.6% | -170.3% | -906.1% |
| Net income | -23 | -88 | -163 | -136 | -84 |
| Net margin | -4.5% | -26.1% | -87.7% | -176.0% | -438.9% |
| Diluted EPS | -$0.47 | -$1.85 | -$4.00 | -$4.02 | -$2.77 |
| Free cash flow | 55 | 9 | -71 | -120 | -241 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open MIRM in Markets.
How Mirum Pharmaceuticals makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Livmarli | $129M | 73.0% |
| Bile Acid Medicines | $47.5M | 27.0% |
See also: MIRM returns
No forecast, no recommendation. This page describes Mirum Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.